Observational studyBMC pediatrics2025
Risk factors for mortality in children with moderate-to-severe ARDS with concurrent hematological or immune-related diseases: a retrospective analysis.
Observational study in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extracorporeal carbon dioxide removal integrated into continuous renal replacement therapy in pediatric patients with ARDS: a retrospective single-center case series.BMC pediatrics · 2026Article
- Editorial: Pediatric respiratory critical illness: etiology, diagnosis, and treatment.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAs a heterogeneous syndrome, acute respiratory distress syndrome (ARDS) patients with comorbidities are significantly more severely ill. We aim to investigate the clinical characteristics and analyze the risk factors for mortality in children with moderate-to-severe acute respiratory distress syndrome (ARDS) who also have concurrent hematological or immune-related diseases.
methodsA retrospective observational study was conducted from September 2020 to May 2022 in the pediatric intensive care unit (PICU) at Children's Hospital of Chongqing Medical University (Chongqing, China). All children with moderate-to-severe ARDS were included and divided into two groups based on the presence or absence of hematological or immune-related diseases. Clinical characteristics, treatment, and outcome data were collected. Univariate logistic regression and multivariate Firth regression analysis were used to identify risk factors for mortality in children with moderate-to-severe ARDS with concurrent hematological or immune-related diseases.
resultsA total of 215 children with moderate-to-severe ARDS were included in the study, of whom 65 had hematological or immune-related diseases (30.2%). These children were older (p < 0.001), had higher Pediatric Index of Mortality 3 scores (p = 0.002), higher lactate levels (p = 0.042), higher rates of positive pathogen detection (p < 0.001), shorter PICU stay (p = 0.023), higher incidence of multiple organ dysfunction syndrome (p = 0.012), and higher 28-day mortality rates (p < 0.001). Firth regression analysis showed that invasive fungal infection (OR = 4.954, 95% CI 0.245-3.158, p < 0.05), use of vasoactive drugs (OR = 7.638, 95% CI 0.524-3.811, p < 0.05), and high-frequency oscillatory ventilation (OR = 6.551, 95% CI 0.134-3.908, p < 0.05) were associated with increased mortality rates in children with moderate-to-severe ARDS with concurrent hematological or immune-related diseases.
conclusionThe incidence of moderate-to-severe ARDS is higher in children with concurrent hematological or immune-related diseases, and their prognosis is worse. In this group, children with invasive fungal infections, greater use of vasoactive drugs, or high-frequency oscillatory ventilation had a higher 28-day mortality rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.